Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors

JAMA Oncology

Volumn 2, Issue 5, 2016, Pages 608-615

  Harris, Marian H ^a   DuBois, Steven G ^b   Bender, Julia L Glade ^c   Kim, Aerang ^d   Crompton, Brian D ^e   Parker, Erin ^e   Dumont, Ian P ^e   Hong, Andrew L ^e   Guo, Dongjing ^e   Church, Alanna ^a   Stegmaier, Kimberly ^e,f   Roberts, Charles W M ^e,f   Shusterman, Suzanne ^e,f   London, Wendy B ^e,f   MacConaill, Laura E ^e,g   Lindeman, Neal I ^f,g   Diller, Lisa ^e,f   Rodriguez Galindo, Carlos ^e,f   Janeway, Katherine A ^e,f  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85010430878     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.5689     Document Type: Article

References (17)

1. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676): 1497-1500.
3. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science. 2013;339(6127):1546-1558.
4. MacConaill LE, Garcia E, Shivdasani P, et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. J Mol Diagn. 2014; 16(6):660-672.
5. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2(1):82-93.
6. Adzhubei IA, Schmidt S, Peshkin L, et al. Amethod and server for predicting damaging missense mutations. Nat Methods. 2010;7(4): 248-249.
7. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-1081.
8. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4(11):e7887.
9. Torres-GarcíaW, Zheng S, Sivachenko A, et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics. 2014;30(15):2224-2226.
10. Thway K, Nicholson AG, Lawson K, et al. Primary pulmonarymyxoid sarcoma with EWSR1-CREB1 fusion: a new tumor entity. Am J Surg Pathol. 2011;35(11):1722-1732.
11. Falconieri G, Bacchi CE, Luzar B. Cutaneous clear cell sarcoma: report of three cases of a potentially underestimated mimicker of spindle cell melanoma. Am J Dermatopathol. 2012;34(6):619-625.
12. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216-231.
13. Crompton BD, Stewart C, Taylor-Weiner A, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014;4(11):1326-1341.
14. Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51): E5564-E5573.
15. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279-284.
16. HawrylukMJ,Wang K, Chmielecki J, et al. Comprehensive next-generation sequencing-based genomic profiling identifies actionable genomic alterations in diverse pediatric tumor types: the Foundation Medicine (FMI) experience. Cancer Res. 2014;74:Abstract 23.
17. Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505 (7484):495-501.